Despite the slowdown in investment in the biopharmaceutical sector, over 10 bioventures in Korea are still planning initial public offerings (IPOs) in the second half of this year.According to securities firms, Curiox, Pharos iBio, SLS Bio, Ensol Biosciences, YBiologics, U2 Bio, Curocell, Pinotbio,
Bio
Lee Han-soo
2023.07.14 16:12